Darzalex Triple Combo Approved in England for Difficult-to-treat Multiple Myeloma
A triple combination of Darzalex (daratumumab), Velcade (bortezomib), and dexamethasone will be available on the National Health Service (NHS) in England for…
Myeloma
Janssen Seeks Final FDA Approval for Darzalex Combo Therapy for Newly Diagnosed Multiple Myeloma
Janssen has is seeking approval from the U.S. Food and Drug Administration (FDA) for Darzalex (daratumumab) — in combination with standard Revlimid (lenalidomide) and…
NantKwest, ProMab Partner to Develop Natural Killer Cell Therapy for Multiple Myeloma, Other Blood Cancers
NantKwest and ProMab Biotechnologies are collaborating to develop a novel immunotherapy for multiple myeloma using natural killer (NK) cells that target the B-cell maturation…
Kyprolis Combo Yields Positive Results as Initial Treatment for Multiple Myeloma
A combination of Kyprolis (carfilzomib) and dexamethasone, already approved for relapsed and refractory multiple myeloma,…
CARsgen to Begin CT053 Clinical Testing in China for Heavily Treated Myeloma Patients
CT053, one of CARsgen Therapeutics‘ lead CAR T-cell therapies, soon will begin clinical testing in China for the treatment of patients with relapsed…
Under-the-skin Formulation as Effective as Intravenous Darzalex for Myeloma Patients, Study Says
An under-the-skin injection of daratumumab is as effective as its intravenous formulation, Darzalex (daratumumab), at reducing tumor burden in multiple myeloma patients, a Phase 3…
FDA Raises Concerns on Safety, Tolerability of Potential Myeloma Therapy Selinexor
The U.S. Food and Drug Administration has raised concerns in its newly released briefing materials over the safety and tolerability of Karyopharm Therapeutics‘ lead compound …
Once-weekly Kyprolis Safe, Effective for Untreated Multiple Myeloma Patients, Study Finds
Treatment with Kyprolis (carfilzomib) once a week is as safe and effective as the twice-weekly regimen used for the initial treatment of multiple myeloma patients, a…
Gamida, Editas Partner to Create Genetically Engineered NAM-NK Cells for Treating Blood, Solid Cancers
Gamida Cell and Editas Medicine have entered a partnership to explore the potential of using gene-editing technology to enhance the activity of certain immune cells…
It’s Off to the Races for eRace Cancer’s 78-year-old Founder and Multiple Myeloma Survivor
In 2003, Don Wright received a daunting diagnosis of multiple myeloma. But not only has the 78-year-old survived, he has thrived. He’s since run 100…
